News

Background Even if randomised trials EXPLORER and LUNAR failed to prove the superiority of rituximab versus placebo in patients with systemic lupus erythematosus, few studies renewed interest for this ...
Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...
Systemic lupus erythematosus (SLE) is a systemic disease with cardiac manifestations, of which pericarditis is the most common (a lifetime risk of 25%) 1 and myocarditis a less common (5–10%)2 but ...
A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...
Malignancy risk in systemic lupus erythematosus (SLE) is about 15% higher than the general age-and-sex-matched population. Hematologic cancers, especially B-cell lymphomas, are about three-fold ...
Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...
Clinicians remain believers in B-cell depletion despite the failure of rituximab in the EXPLORER, LUNAR, and BELONG clinical trials. 1–3 Additional studies suggested that the B-cell depletion that ...
Background/ Purpose Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ ...
Background Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease, which causes systemic involvement, including within the central nervous system (CNS). Since biomarkers for ...
Objective Whereas genetic susceptibility for Systemic Lupus Erythematosus (SLE) has been well explored, the triggers for clinical disease flares remain elusive. To investigate relationships between ...
Background Despite optimal treatment, lupus nephritis (LN) remains associated with irreversible kidney damage. 1 A better understanding of the mechanisms underlying LN pathogenesis is needed to ...
Background Kidney involvement is common in lupus. Lupus and kidney diseases incur poor outcomes in people from racial/ethnic minority groups. Previous studies have utilized the national registry of ...